Antibody to an IL-17 receptor like protein

• US 6,849,719 B2
• Filed: 03/02/2001
• Issued: 02/01/2005
• Est. Priority Date: 09/17/1997
• Status: Expired due to Fees

• Current Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Original Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Inventors: Ruben, Steven M., Shi, Yanggu
• Primary Examiner(s): Spector, Lorraine
• Assistant Examiner(s): Jiang, Dong
• Application Number:
  US09/796,844
• Publication Number:
  US 20040096935A1
• Time in Patent Office: 1,432 Days
• Field of Search: 530/388.22, 530/388.1, 530/387.9, 530/387.3, 530/350, 424/130.1, 424/133.1, 424/135.1, 424/139.1
• US Class Current: 530/388.22
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/54 Interleukins [IL]
• CPC Class Codes: C07K 14/7155 for interleukins [IL]
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 2799/026 where the vector is derived from a baculovirus
• CPC Class Codes: G01N 2333/715 for cytokines; for lymphokines; for interferons

Abstract

The present invention relates to a novel IL17RLP protein which is a member of the interleukin (IL)-17 receptor family. In particular, isolated nucleic acid molecules are provided encoding the human IL17RLP protein. IL17RLP polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of IL17RLP activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating, diagnosing, detecting, and/or preventing immune system-related disorders.

Claims

1. An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

(a) amino acid residues −

19 to +407 of SEQ ID NO;

2;

(b) amino acid residues −

18 to +407 ofSEQ ID NO;

2;

(c) amino acid residues +1 to +407 of SEQ ID NO;

2;

(d) amino acid residues +1 to +271 of SEQ ID NO;

2; and

(e) amino acid residues −

5 to +271 of SEQ ID NO;

2.

2. The antibody or fragment thereof of claim 1 that specifically binds protein (a).

3. The antibody or fragment thereof of claim 1 that specifically binds protein (b).

4. The antibody or fragment thereof of claim 1 that specifically binds protein (c).

5. The antibody or fragment thereof of claim 1 that specifically binds protein (d).

6. The antibody or fragment thereof of claim 5, wherein said protein specifically bound by said antibody or fragment thereof is glycosylated.

7. The antibody or fragment thereof of claim 5 which is a monoclonal antibody.

8. The antibody or fragment thereof of claim 5 which is a polyclonal antibody.

9. The antibody or fragment thereof of claim 5 which is a human antibody.

10. The antibody or fragment thereof of claim 5 selected from the group consisting of:

(a) a chimeric antibody;

(b) a humanized antibody;

(c) a single chain antibody; and

(d) a Fab fragment.

11. The antibody or fragment thereof of claim 5 which is labeled.

12. The antibody of claim 11, wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) a bioluminescent label.

13. The antibody or fragment thereof of claim 5, wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

14. The antibody or fragment thereof of claim 5, wherein said antibody or fragment thereof specifically binds to said protein in an ELISA assay.

15. The antibody or fragment thereof of claim 1 that specifically binds protein (e).

16. A method of detecting Interleukin-17 Receptor Like Protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or frament thereof of claim 1 under conditions that allow formation of an antibody and lnterleukin-17 Receptor Like Protein complex; and

(b) detecting said complex in the biological sample, wherein the presence of said complex indicates the presence of Interleukin-17 Receptor Like Protein.

17. An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

(a) an amino acid sequence of the full length protein encoded by the cDNA in ATCC Deposit No. 209198;

(b) an amino acid sequence of the full length protein, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209198; and

(c) an amino acid sequence of the extracellular domain of the protein encoded by the cDNA in ATCC Deposit No. 209198.

18. The antibody or fragment thereof of claim 17 that specifically binds protein (a).

19. The antibody or fragment thereof of claim 17 that specifically binds protein (b).

20. The antibody or fragment thereof of claim 17 that specifically binds protein (c).

21. The antibody or fragment thereof of claim 20, wherein said protein specifically bound by said antibody or fragment thereof is glycosylated.

22. The antibody or fragment thereof of claim 20 which is a monoclonal antibody.

23. The antibody or fragment thereof of claim 20 which is a polyclonal antibody.

24. The antibody or fragment thereof of claim 20 which is a human antibody.

25. The antibody or fragment thereof of claim 20 selected from the group consisting of:

(a) a chimeric antibody;

(b) a humanized antibody;

(c) a single chain antibody; and

(d) a Fab fragment.

26. The antibody or fragment thereof of claim 20 which is labled.

27. The antibody of claim 26, wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) a bioluminescent label.

28. The antibody or fragment thereof of claim 20, wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

29. The antibody or fragment thereof of claim 20, wherein said antibody or fragment thereof specifically binds to said protein in an ELISA assay.

30. A method of detecting lnierleukin-17 Receptor Like Protein in a biological sample comprising

(a) contacing the biological sample with the antibody or fragment thereof of claim 17 under conditions that allow formation of an antibody and Interleukin-17 Receptor Like Protein complex;

and

(b) detecting said complex in the biological sample, wherein the presence of said complex indicates the presence of Interleukin-17 Receptor Like Protein.

31. An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein selected from the group consisting of:

(a) amino acid residues −

19 to +407 of SEQ ID NO;

2;

(b) amino acid residues −

18 to +407 of SEQ ID NO;

2;

(c) amino acid residues +1 to +407 of SEQ ID NO;

2;

(d) amino acid residues +1 to +271 of SEQ ID NO;

2; and

(e) amino acid residues −

5 to +271 of SEQ ID NO;

2;

wherein said isolated antibody or fragment thereof specifically binds to said protein.

32. The antibody or fragment of claim 31 obtained from an animal immunized with protein (a).

33. The antibody or fragment of claim 31 obtained from an animal immunized with protein (b).

34. The antibody or fragment of claim 31 obtained from an animal immunized with protein (c).

35. The antibody or fragment of claim 31 obtained from an animal immunized with protein (d).

36. The antibody or fragment of claim 31 obtained from an animal immunized with protein (e).

37. The antibody or fragment of claim 31 which is a monoclonal antibody.

38. The isolated antibody or fragment thereof of claim 31 which is selected from the group consisting of:

(a) a chimeric antibody;

(b) a humanized antibody;

(c) a single chain antibody; and

(d) a Fab fragment.

39. An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein selected from the group consisting of:

(a) an amino acid sequence of the full length protein encoded by the cDNA in ATCC Deposit No. 209198;

(b) an amino acid sequence of the full length protein, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209198; and

(c) an amino acid sequence of the extracellular domain of the protein encoded by the cDNA in ATCC Deposit No. 209198;

wherein said isolated antibody or fragment thereof specifically binds to said protein.

40. The antibody or fragment of claim 39 obtained from an animal immunized with protein (a).

41. The antibody or fragment of claim 39 obtained from an animal immunized with protein (b).

42. The antibody or fragment of claim 39 obtained from an animal immunized with protein (c).

43. The antibody or fragment of claim 39 which is a monoclonal antibody.

44. The isolated antibody or fragment thereof of claim 39 which is selected from the group consisting of:

(a) a chimeric antibody;

(b) a humanized antibody;

(c) a single chain antibody; and

(d) a Fab fragment.

45. An isolated monoclonal antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

(a) amino acid residues −

19 to +407 of SEQ ID NO;

2;

(b) amino acid residues −

18 to +407 of SEQ ID NO;

2;

(c) amino acid residues +1 to +407 of SEQ ID NO;

2;

(d) amino acid residues +1 to +271 of SEQ ID NO;

2; and

(e) amino acid residues −

5 to +271 of SEQ ID NO;

2.

46. The antibody or fragment thereof of claim 45 that specifically binds protein (a).

47. The antibody or fragment thereof of claim 45 that specifically binds protein (b).

48. The antibody or fragment thereof of claim 45 that specifically binds protein (c).

49. The antibody or fragment thereof of claim 45 that specifically binds protein (d).

50. The antibody or fragment thereof of claim 49, wherein said protein specifically bound by said antibody or fragment thereof is glycosylated.

51. The antibody or fragment thereof of claim 49 which is a human antibody.

52. The antibody or fragment thereof of claim 49 selected from the group consisting of:

(a) a chimeric antibody;

(b) a humanized antibody;

(c) a single chain antibody; and

(d) a Fab fragment.

53. The antibody or fragment thereof of claim 49 which is labeled.

54. The antibody of claim 53, wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) a bioluminescent label.

55. The antibody or fragment thereof of claim 49, wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

56. The antibody or fragment thereof of claim 49, wherein said antibody or fragment thereof specifically binds to said protein in an ELISA assay.

57. The antibody or fragment thereof of claim 45 that specifically binds protein (e).

58. A method of detecting Inerleukin-17 Receptor Like Protein in a biological sample comprsing:

(a) contacting the biological sample with the antibody or fragment thereof of claim 45 under conditions that allow formation of an antibody and Interleukin-17 Receptor Like Protein complex; and

(b) detecting said complex in the biological sample, wherein ihe presence of said complex indicates the presence of Interleukin-17 Receptor Like Protein.

59. An isolated monoclonal antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

(a) an amino acid sequence of the full length protein encoded by the cDNA in ATCC Deposit No. 209198;

(b) an amino acid sequence of the full length protein, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209198; and

(c) an amino acid sequence of the extracellular domain of the protein encoded by the cDNA in ATCC Deposit No. 209198.

60. The antibody or fragment thereof of claim 59 that specifically binds protein (a).

61. The antibody or fragment thereof of claim 59 that specifically binds protein (b).

62. The antibody or fragment thereof of claim 59 that specifically binds protein (c).

63. The antibody or fragment thereof of claim 62, wherein said protein specifically bound by said antibody or fragment thereof is glycosylated.

64. The antibody or fragment thereof of claim 62 which is a human antibody.

65. The isolated antibody or fragment thereof of claim 62 selected from the group consisting of:

(a) a chimeric antibody;

(b) a humanized antibody;

(c) a single chain antibody; and

(d) a Fab fragment.

66. The antibody or fragment thereof of claim 62 which is labeled.

67. The antibody of claim 66, wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) a bioluminescent label.

68. The antibody or fragment thereof of claim 62, wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

69. The antibody or fragment thereof of claim 62, wherein said antibody or fragment thereof specifically binds to said protein in an ELISA assay.

70. A method of detecting Interleukin-17 Receptor like Protein in a biological sanple comprising:

(a) contacting the biological sample with the antibody or fragment thereof of claim 59 under conditions that allow formation of an antibody and Interleukin-17 Receptor Like Protein complex; and

(b) detecting said complex in the biological sample, wherein the presence of said complex indicates the presence of Interleukin-17 Receptor Like Protein.

71. An isolated antibody or fragment thereof that specifically binds to a protein expressed on the surface of a cell, wherein said protein is selected from the group consisting of:

(a) an amino acid sequence of the extracellular domain of the protein encoded by the cDNA in ATCC Deposit No. 209198;

(b) an amino acid sequence of the full length protein encoded by the cDNA in ATCC Deposit No. 209198;

(c) an amino acid sequence of the full length protein, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209198;

(d) an amino acid sequence of the mature protein encoded by the cDNA in ATCC Deposit No. 209198

(e) amino acid residues −

19 to +407 of SEQ ID NO;

2;

(f) amino acid residues −

18 to +407 of SEQ ID NO;

2;

(g) amino acid residues +1 to +407 of SEQ ID NO;

2;

(h) amino acid residues +1 to +271 of SEQ ID NO;

2; and

(i) amino acid residues −

5 to +271 of SEQ ID NO;

2.

72. The antibody or fragment thereof of claim 71 which is a monoclonal antibody.

73. The antibody or fragment thereof of claim 71 which is a polyclonal antibody.

74. The isolated antibody or fragment thereof of claim 71 selected from the group consisting of:

(a) a chimeric antibody;

(b) a humanized antibody;

(c) a single chain antibody; and

(d) a Fab fragment.

75. The antibody or fragment thereof of claim 71 which is labeled.

76. The antibody of claim 75, wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label;

(d) a bioluminescent label.